CHA Biotech Co. Ltd
Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more
CHA Biotech Co. Ltd - Asset Resilience Ratio
CHA Biotech Co. Ltd (085660) has an Asset Resilience Ratio of 4.29% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how CHA Biotech Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CHA Biotech Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩99.90 Billion | 4.29% |
| Total Liquid Assets | ₩99.90 Billion | 4.29% |
Asset Resilience Insights
- Limited Liquidity: CHA Biotech Co. Ltd maintains only 4.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CHA Biotech Co. Ltd Industry Peers by Asset Resilience Ratio
Compare CHA Biotech Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for CHA Biotech Co. Ltd (2008–2024)
The table below shows the annual Asset Resilience Ratio data for CHA Biotech Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.74% | ₩104.10 Billion | ₩2.19 Trillion | -4.59pp |
| 2023-12-31 | 9.34% | ₩161.09 Billion | ₩1.73 Trillion | -5.49pp |
| 2022-12-31 | 14.83% | ₩238.32 Billion | ₩1.61 Trillion | -6.59pp |
| 2021-12-31 | 21.43% | ₩328.90 Billion | ₩1.54 Trillion | -4.75pp |
| 2020-12-31 | 26.17% | ₩343.83 Billion | ₩1.31 Trillion | +0.99pp |
| 2019-12-31 | 25.18% | ₩292.86 Billion | ₩1.16 Trillion | -0.10pp |
| 2018-12-31 | 25.29% | ₩239.59 Billion | ₩947.53 Billion | -9.23pp |
| 2017-12-31 | 34.52% | ₩273.95 Billion | ₩793.61 Billion | -7.57pp |
| 2016-12-31 | 42.09% | ₩323.62 Billion | ₩768.93 Billion | +26.34pp |
| 2015-12-31 | 15.75% | ₩101.53 Billion | ₩644.83 Billion | +2.24pp |
| 2014-12-31 | 13.50% | ₩83.85 Billion | ₩620.88 Billion | -13.12pp |
| 2013-12-31 | 26.63% | ₩182.51 Billion | ₩685.47 Billion | +6.88pp |
| 2012-12-31 | 19.75% | ₩102.39 Billion | ₩518.47 Billion | -2.98pp |
| 2011-12-31 | 22.73% | ₩107.96 Billion | ₩475.02 Billion | +18.93pp |
| 2010-12-31 | 3.80% | ₩12.70 Billion | ₩334.30 Billion | -1.74pp |
| 2009-12-31 | 5.54% | ₩12.65 Billion | ₩228.35 Billion | -24.92pp |
| 2008-12-31 | 30.45% | ₩31.64 Billion | ₩103.88 Billion | -- |